JAK1 and systemic lupus erythematosus: Solcitinib (GSK2586184), a selective JAK1 inhibitor, was going to be tested in a Phase II trial (NCT01777256) in patients with active non-renal SLE; the trial was stopped early after the recruitment of 50 patients, due to inadequate efficacy.